555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [miền bắc hôm nay]
Oct 17, 2024 · Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination …
6 days ago · The current standard of treatment for ER+/HER2− advanced breast cancer is an aromatase inhibitor plus a CDK4/6 inhibitor, but many of these patients develop a treatment …
Aug 5, 2025 · The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced …
UCI 22-222: A Phase III, Mutlicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant versus Alpelisib Plus Fulvestrant in Patients with …
2 days ago · We report dose escalation and expansion data from a trial of H3B-6545 (a novel selective ER covalent antagonist that inactivates wild-type and mutant ERα) in women with …
-No prior chemotherapy for advanced or metastatic breast cancer. Subjects who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, as long as they have had a …
Aug 8, 2025 · We therefore selected an alternative chemotherapy regimen unlikely to result in drug-drug interactions (DDI) due to a lack of CYP-mediated metabolism of the chemotherapy …
Treating metastatic breast cancer can be difficult, as it often requires a combination of therapies and ongoing adjustments to treatment plans. Talzenna has been approved for use in patients …
Aug 12, 2025 · The U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) highlighting vepdegestrant for the treatment of patients with estrogen …
6 days ago · New data show that the new CDK4/6 inhibitor with fulvestrant yields a notable PFS benefit in HR+/HER2- advanced breast cancer but at the cost of more toxicities.
Bài viết được đề xuất: